Search results
Results from the WOW.Com Content Network
Streptokinase is a thrombolytic medication activating plasminogen by nonenzymatic mechanism. [1] As a medication it is used to break down clots in some cases of myocardial infarction (heart attack), pulmonary embolism, and arterial thromboembolism. [2] The type of heart attack it is used in is an ST elevation myocardial infarction (STEMI). [3]
Thrombolysis, also called fibrinolytic therapy, is the breakdown of blood clots formed in blood vessels, using medication. It is used in ST elevation myocardial infarction, stroke, and in cases of severe venous thromboembolism (massive pulmonary embolism or extensive deep vein thrombosis). [citation needed]
A blood clot that reaches your brain can cause a stroke. Symptoms of a stroke include sudden: Numbness or weakness, often on one side of your body or face. Confusion.
However, streptokinase causes systemic fibrinolytic state and can lead to bleeding problems. Tissue plasminogen activator (tPA) is a different enzyme that promotes the degradation of fibrin in clots but not free fibrinogen. [14] This drug is made by transgenic bacteria and converts plasminogen into the clot-dissolving enzyme, plasmin. [15]
It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations. Uses
Tissue-type plasminogen activator, short name tPA, is a protein that facilitates the breakdown of blood clots. It acts as an enzyme to convert plasminogen into its active form plasmin, the major enzyme responsible for clot breakdown.
[3] [6] [7] Because irreversible injury occurs within 2–4 hours of the infarction, there is a limited window of time available for reperfusion to work. [ citation needed ] Thrombolytic drugs are contraindicated for the treatment of unstable angina and NSTEMI [ 3 ] [ 8 ] and for the treatment of individuals with evidence of cardiogenic shock .
GMR agreed to pay a reported fee of nearly 50 million pounds ($62 million), taking the amount paid for stakes in the eight franchises — ranging to 49% to 100% — to over 500 million ($620 million).